How much funding has Therini Bio raised?

Therini Bio has raised $75.0M in total funding, most recently a Series A round.

Who are Therini Bio's investors?

Therini Bio's investors include Angelini Ventures.

When was Therini Bio founded?

Therini Bio was founded in 2019.

Where is Therini Bio headquartered?

Therini Bio is headquartered in Sacramento, California, United States.

What industry is Therini Bio in?

Therini Bio operates in Biotech.

How many employees does Therini Bio have?

Therini Bio has 1-10 employees.

Therini Bio

Therini

Sacramento, United States · Founded 2019 · $75.0M raised

Biotech

Headquarters: Sacramento, California
Employees: 1–10
Founded: 2019
Business Model: B2B

Website: therinibio.com
Total Funding: $75.0M
Last Round: $75.0M Series AApr 2023
Rounds: 1

About

Therini Bio is a Sacramento-based clinical-stage biopharmaceutical company founded in 2019 by Katerina Akassoglou, a professor at UCSF and senior investigator at the Gladstone Institutes. The company's science is based on the discovery that a cryptic epitope on fibrin (a blood-clotting factor) drives chronic innate immune activation and neurodegeneration when fibrin leaks outside blood vessels into brain tissue. Its lead candidate THN391 is a monoclonal antibody that selectively targets this inflammatory fibrin epitope to block microglial and macrophage activation. THN391 completed a Phase Ia trial in healthy volunteers in 2025, demonstrating tolerability. A $39M Series A extension in May 2025 (with Angelini Ventures) will fund a Phase Ib trial for THN391 and development of a fibrin/VEGF bispecific for retinal diseases. Total raised is approximately $62M+ with backing including Eli Lilly.

Summary

Therini Bio is a Biotech company based in Sacramento, United States, founded in 2019. It has raised $75.0M in total across 1 round, most recently a $75.0M Series A round in Apr 2023. Investors include Angelini Ventures.